The presence of preexisting (memory) or de novo donor-specific HLA antibodies (DSAs) is a known barrier to successful long-term organ transplantation. Yet, despite the fact that laboratory tools and our understanding of histocompatibility have advanced significantly in recent years, the criteria to define presence of a DSA and assign a level of risk for a given DSA vary markedly between centers. A collaborative effort between the American Society for Histocompatibility and Immunogenetics and the American Society of Transplantation provided the logistical support for generating a dedicated multidisciplinary working group, which included experts in histo- 
| INTRODUCTION
The presence of preexisting (memory) or de novo donor-specific HLA antibodies (DSAs) is a known barrier to successful long-term organ transplant. 1 Yet, the criteria to define and assign a level of risk for a given DSA vary markedly between centers, despite the fact that available laboratory tools and our understanding of histocompatibility have advanced significantly in recent years. Unfortunately, much of our current clinical practice is based on transplant survival studies that were designed in the time of older technologies, confounding our ability to interpret and implement those results into current clinical practice or design new clinical studies. Consequently, there is a need to update guidelines for antibody testing and patient risk assessment to enable clinical programs to design personalized immunosuppression protocols.
A collaborative effort between the American Society for Histocompatibility and Immunogenetics and the American Society of Transplantation provided the logistical support for generating a dedicated multidisciplinary working group that included experts in histocompatibility as well as kidney, liver, heart, and lung transplantation. The goals were to perform a critical review of biologically driven, state-of-the-art, clinical diagnostics literature where comprehensive account of methodology was provided and to provide clinical practice recommendations based on expert assessment of the strength of evidence ( Figure 1 ). A complete list of publications that were reviewed by the working group is provided in lacking to support one approach over another, and (2) for a given patient, the risk of memory or de novo alloimmunity, and the requirements for risk mitigation therapies, varies significantly based on the target organ (most notably in the case of liver transplants). 
| DEFINING THE PRESENCE/ABSENCE OF AN HLA ANTIBODY

| TERMINOLOGY
The survey results, combined with reviews of the relevant literature, made it evident that there is confusion with terminology in the community. It was agreed there must be clarity and consistent use of terms to allow comparison between research studies, as well as clinical outcomes, and to facilitate improvement in practice guidelines and health system policy.
Specifically, the following major terminology and misuse of terms were identified: Determination of antibody titer is important as it is likely to have implications on the injurious qualities of that antibody and a reference point for determining efficacy of desensitization therapy. 5 2. 0% Calculated PRA (cPRA) ≠ immunologically naïve. The fact that a patient has no detectable HLA antibodies does not infer that he or she 
Strength of Recommendation EO
There is no specific evidence to address recommendaƟon, however it aligns with standard of care and would be agreed by a majority of experts that no specific evidence on the topic needs to be generated, nor would it be expected to be generated
There is absence of evidence and/or the working group expert opinion only was used, or RCT or Very strong evidence of associaƟon with no confounders Strong evidence of associaƟon or evidence of a dose response gradient
ObservaƟonal study
Other types of studies or serious limitaƟons to study quality is immunologically naïve with regard to HLA antigens. It is entirely possible that a nontransplanted patient has been exposed and responded to an allo-HLA antigen through pregnancy or transfusion yet does not have a detectable HLA antibody in the current sera.
3. Acceptable HLA mismatch ≠ immunologically naïve. The term "unacceptable HLA antigens" is used in the context of listing a patient's HLA antibody specificities in UNet to avoid donor offers that the clinical program is not willing to cross due to the risk associated with a memory response. Not uncommonly, it is assumed that the remaining "acceptable antigens" infers that there is no immune memory or that there is no HLA antibody specific for the "acceptable antigen." This is entirely a false premise -in many instances just because a DSA MFI is below the program's "risk threshold" does not mean the antibody does not exist and that the recipient is immunologically naïve to that mismatch and therefore at no or minimal risk.
4.
Pretransplant DSA titer ≠ posttransplant memory response. It is often inferred that the amount of antibody pretransplant can be used to predict the risk and intensity of the posttransplant recall response. This is completely without basis -at present, we have no tools to determine if a low titer antibody will remain low or rapidly increase in titer.
Complement (C') binding activity in vitro ≠ in vivo c' binding activ-
ity. While certain antibody subclasses do have higher affinity for C1q binding, complement activation is largely a consequence of a high concentration of DSAs. 4, 6, 7 Indeed, it has been shown that activation of C1q requires the presence of 6 antibody molecules in close proximity. 8 Therefore, while emerging data suggest C1q-positive DSAs may indicate a potential risk for adverse graft outcomes, more research in this regard is required to clearly demonstrate its distinct utility. 10 6. Eplet ≠ epitope. A commonly misused term is "epitope" instead of "eplet." "Epitope" refers to the complete contact area between an antibody and an antigen. "Eplet" is a portion of the epitope that in theory forms the third CDR of the immunoglobulin variable heavy chain (CDR H3) antibody binding site, defined purely based on amino acid mismatching between donor and recipient (i.e., represents the potential functional epitope of the antibody determining specificity, whereas the entire structural epitope, composed of the binding by all 6 CDRs, determines antibody avidity). 11, 12 Currently, only a subset of the theoretical eplets have been proved to be antigenic.
| QUALITY AND COMPREHENSIVE USE OF HLA DIAGNOSTICS
It was identified that the quality and comprehensive use of HLA diagnostics vary greatly in the published literature. This is in part related to the retrospective nature of many reports that examine longitudinal outcomes in cohorts before 2010, after which UNOS started to mandate more comprehensive HLA loci typing as well as solid phase testing for HLA antibodies. Key gaps remain that need to be considered in interpreting the literature: 4. Failure to consider shared epitopes between solid phase beads leads to underrecognition of DSA. While the aforementioned MFI cut-off between 1000 and 1500 units is generally optimal for recognition of a DSA specificity, it is nonetheless a guideline and not an absolute. When a number of beads share the same DSA epitope, it is entirely possible to have a DSA with the MFI <1000 on all beads.
Knowledge of shared epitopes is therefore essential for proper interpretation of SAB assays.
To improve "precision" and "personalized" medicine, the consensus was that comprehensive HLA diagnostics must become the standard of care and most certainly have to be imbedded in clinical trial research going forward. The STAR Working Group recommendations for HLA antigen typing and antibody testing are summarized in Figure 2 .
| IMMUNE MEMORY
Immunologic memory is the ability of the immune system to respond rapidly and with vigor on reencounter with the same antigen. Modern donor antigens, provide another potential source of alloreactive memory T cells in transplant recipients. 15, 16 Given that immune memory is a known barrier to graft survival, 17 although its impact can vary by organ type, the STAR Working Group recommendations are aimed at detecting and evaluating the immune status of the patient. That said, it is important to recognize, at least as currently measured, that the in vitro assessment of immune memory has severe limitations and gaps that fail to incorporate aspects of well-described immunobiology.
| CLINICAL MEASUREMENT OF IMMUNE MEMORY
Currently, classification of patients as "sensitized" or "naïve" is strongly influenced by the most recent circulating HLA antibody test -percent PRA and specific HLA antibody identification. While this information is beneficial to predict lymphocyte crossmatch results, it does not provide complete and accurate information regarding the patient's sensitization history and his or her likelihood to have a recall memory response against the transplanted organ.
Specifically, patients with 0% PRA in a current serum sample may have had historic HLA antibodies after a sensitizing event that may or may not be apparent to the clinician based on availability of sera and frequency and length of historic HLA antibody testing.
Moreover, recent literature demonstrates that HLA specific B cell memory may be present even in the absence of detectable HLA antibodies. 18, 19 The meeting highlighted that our current "memory assays" are limited to detecting circulating HLA antibodies at a specific time-point (ie, flow PRA and the SAB assays) and thus focus on only a small portion of the memory alloimmune response. Clearly, we are only beginning to scratch the surface of detecting donor-specific B and T cell memory (eg, interferonγ enzyme-linked immunosorbent spot [ELISpot] assay) pretransplant. 20 The STAR Working Group developed definitions for alloimmune memory (Figure 3 ) and recommendations to evaluate a patient's potential for alloimmune memory (Figure 4) . 
| PRIMARY (NAÏVE OR DE NOVO) ALLOIMMUNE RESPONSE
It is difficult to document that a patient is truly "naïve" for a given • Latent Potential for an Alloimmune Memory Response: One or more of,
• A history of a sensitizing event;
• Non-DSA HLA antibody detected at one or more time points prior to transplant;
• Non-DSA HLA antibody detected at the time of transplant.
• Active Potential for an Alloimmune Memory Response: Donor specific antibody (DSA) are present at the time of transplant or in a historical serum sample tested, representing a risk for DSA associated injury.
• Alloimmune Memory Response: The development post-transplant at any time of an antibody that was detected prior to transplant and/or the development of a new DSA in the first 2 weeks post-transplant. Caveat to consider:
• Development of a new DSA between 2 weeks and 3 months may still represent memory. these are broad guidelines and represent an area for further study and refinement to determine the relative contribution of memory and primary alloimmunity early (ie, <6 months) posttransplant.
However, the distinction may prove very relevant as literature is reporting differences in outcomes related to memory versus de novo DSA-associated ABMR. 24, 25 Similarly, whether treatment protocols are equally effective for both memory and primary alloimmunity requires further research.
Literature rigorously defining an alloimmune response as de novo has reported that the level of HLA whole antigen mismatch does not accurately reflect the immunogenic risk of a given donor to elicit a de novo alloresponse. 26 Indeed, for a given level of HLA serologic antigen mismatch, at the molecular level, the donor and recipient of a donor-recipient pair may be very similar to one another or quite disparate. New computational tools are emerging that allow accurate quantitation at the HLA molecular mismatch level (eg, in terms of amino acid polymorphisms or differences in electrostatic charge) for any donor-recipient combination, which may allow more accurate assessment of a patient's risk for a de novo alloimmune response postransplant. 27, 28 While the optimal computational methods and threshold values to assign risk are yet to be determined and validated, especially in diverse genetic backgrounds and across all organ transplants, the STAR Working Group saw this area as one holding great promise for the field requiring immediate investment. It may allow for personalized immunosuppression and, in particular, minimization to avoid unwanted side effects.
| ALLOIMMUNE RISK ASSESSMENT
Based on the aforementioned discussion of the biology of memory and primary alloimmune responses, the STAR Working Group constructed a general framework for assigning risk independently for memory and primary alloimmune responses at the time of transplant. Summarized in Table 1 , the framework proposes that risk can be broadly assigned by using currently available state-of-the-art HLA diagnostics. The novel aspect of this framework is the assignment of 2 types of risk (eg, 1 for memory and 1 for de novo alloimmunity).
While the de novo risk assignment on the basis of molecular HLA
mismatch is yet to be optimized, the STAR Working Group saw the creation of the framework as critical to foster research in the field of HLA immunogenicity and to ultimately define immunodominant HLA epitopes driving TCMR and ABMR. The use of the framework is seen as allowing individual transplant programs to first and foremost define the memory and primary alloimmune risks present for a given patient and organ transplant type and then to either avoid the risk or develop tailored induction and maintenance immunosuppressive therapies to address the risk. As stated at the outset, protocols vary widely across clinical programs, and the literature does not currently have high-quality evidence to recommend one protocol over another. It is hoped that this framework will drive clinical research to address this gap.
| ORGAN-SPECIFIC HLA DIAGNOSTIC ASSESSMENT GUIDELINES
There was broad consensus among the organ-specific groups for the recommendations contained in Figures 1 to 3 . However, immediate pretransplant evaluation and posttransplant assessment varied among the organ-specific groups, and these are reflected in Table 2 , mainly concerning the grade and strength of the recommendations.
Of note, while there was general agreement in regard to the need for posttransplant DSA monitoring, especially in the context of memory, the lack of high-quality evidence precludes the STAR Working Group from making any specific recommendations as to the frequency and duration-at this point, it should be a program-specific decision.
| KEY KNOWLEDGE GAPS
The STAR Working Group identified general as well as organ-specific gaps in the current knowledge that should be addressed within the following broad categories:
Risk Stratification for Memory and Primary Alloimmune
Responses
The literature review, as well as the survey, elucidated the lack of integration between HLA antibody information and current knowledge of immunobiological processes as a tool to guide clinical practice. 
Desensitization/crossing HLA antibody barriers
Multiple desensitization protocols are currently available. [29] [30] [31] [32] However, it is not clear how to determine the optimal patient population who may respond to each of these approaches, or to predict whether the response will be sufficient to bridge those patients to transplantation, or if a specific protocol is even required in the case of liver transplants. Assays to monitor the efficacy of these treatments are lacking, and thus the ability to compare between the different protocols is limited. Moreover, the effectiveness of desensitization in targeting memory (especially B cells) is completely unknown. It is currently not clear whether some DSA attributes are more detrimental than others and what the relationships are between these characteristics (eg, complement binding antibodies, titers, antibody subclasses, the dynamics of isotype switching over time, the impact of FcγR genotypes, etc.). 33
Posttransplant monitoring
Determining the usefulness of regular screening for DSA, the frequency, and the associated cost-benefit is required for both memory and de novo alloimmune monitoring in all organs. While the epidemiology of memory and de novo alloimmunity and their natural history are becoming clearer, especially for kidneys, there is a need for their further evaluation in all organs, especially in the context of nonwhite genetics, to determine risk factors and rates of progression-critical for the future design of prevention and intervention trials. The use of HLA diagnostics in monitoring response to treatment is also in its infancy.
As more therapeutic agents become available, defining a noninvasive tool (eg, DSA attributes, other novel assays) that correlates with effective therapy will be required).
| CALL FOR IMMEDIATE ACTION
Two key themes that emerged from the Working Group are the following. First, currently, there are no minimal guidelines for the details of information required for publications related to HLA antibodies in the context of solid organ transplantation. The lack of sufficient details prohibits in-depth understanding of the differences and similarities between studies and results in confusion. This can be resolved by requiring minimal criteria for publication. Second, there is a pressing need to create centralized registries for highly sensi- 
